Lenvima

News

Two packets and two vials of different doses of Imfinzi

ASCO26: AZ triplet makes waves in frontline liver cancer

EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.

News

MSD, Eisai report setback in first-line kidney cancer trial

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.

News

Eisai settles Lenvima patent dispute with Torrent Pharma

A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

News

Eisai says patent win blocks Lenvima generic to 2036

Eisai has won a lawsuit blocking FDA approval of Shilpa's generic of cancer blockbuster Lenvima until 2036, although the verdict could go to appeal.

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

ASCO26: AZ triplet makes waves in frontline liver cancer

MSD, Eisai report setback in first-line kidney cancer trial

Eisai settles Lenvima patent dispute with Torrent Pharma

MSD, Eisai abandon combination trial in liver cancer

Eisai says patent win blocks Lenvima generic to 2036

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Lenvima

Editor's Picks